Breast Cancer 2011-New Aspects

被引：16

作者：

Kuemmel, S. ^{[1
]}

Kolberg, H. C.

Lueftner, D. ^{[2
]}

Lux, M. P. ^{[3
]}

Maass, N. ^{[4
]}

Schuetz, F. ^{[5
]}

Fasching, P. A. ^{[3
,6
]}

Fehm, T. ^{[7
]}

Janni, W. ^{[8
]}

机构：

[1] Evang Huyssens Stiftung Knappschaft GmbH, Kliniken Essen Mitte, Klin Senol, D-45136 Essen, Germany

[2] Campus Charite Mitte, Med Klin & Poliklin 2, Berlin, Germany

[3] Univ Klinikums Erlangen, Frauenklin, Erlangen, Germany

[4] Univ Klinikums Aachen, Frauenklin, Aachen, Germany

[5] Univ Klinikums Heidelberg, Frauenklin, Heidelberg, Germany

[6] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Dept Med, Los Angeles, CA 90095 USA

[7] Univ Frauenklin Tubingen, Tubingen, Germany

[8] Univ Klinikums Dusseldorf, Frauenklin, Dusseldorf, Germany

来源：

GEBURTSHILFE UND FRAUENHEILKUNDE | 2011年 / 71卷 / 11期

关键词：

breast cancer; therapy; prognosis; molecular marker; studies; HORMONE REPLACEMENT THERAPY; ADJUVANT CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; HEREDITARY BREAST; ANTICANCER DRUGS; ZOLEDRONIC ACID; DOSE-DENSE; P-AKT; TRASTUZUMAB; PTEN;

D O I：

10.1055/s-0031-1280313

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The treatment options for primary and metastatic breast cancer patients as well as the characteristics considered for therapy decision continue to become more diverse. New target therapies in combination with established chemotherapy regimens extend the range, however, potentially promising combinations do not always result in a benefit for the patient. Latest pharmacogenomics results hint towards prognosis and predictive factors, which do not only focus on the individual properties of the tumor, they also consider the hereditary genetics of the patient. As a result, state of the art therapy decision includes classical clinical as well as modern molecular biomarkers, however, pharmacoeconomic aspects continue to increase in importance in physicians' treatment algorithms. This review builds on the recent congresses, which present new data on the treatment of breast cancer. The last included one is the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011.

引用

页码：939 / 953

页数：15

共 106 条

[1] Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03-A multicenter, randomized phase II study [J].

Alba, E. ;

Chacon, J. I. ;

Lluch, A. ;

Garcia-Estevez, L. ;

Anton, A. ;

Cirauqui, B. ;

Lopez Garcia-Asenjo, J. A. ;

Carrasco, E. M. ;

Rodriguez, C. ;

Escudero, M. J. ;

Sanchez, A. ;

Ribelles, N. ;

Romero, C. ;

Alvarez, J. ;

Albanell, J. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[2] Prognosis and Outcome of Small (≤1 cm), Node-Negative Breast Cancer on the Basis of Hormonal and HER-2 Status [J].

Amar, Surabhi ;

McCullough, Ann E. ;

Tan, Winston ;

Geiger, Xochiquetzal J. ;

Boughey, Judy C. ;

McNeil, Rebecca B. ;

Coppola, Kyle E. ;

McLaughlin, Sarah A. ;

Palmieri, Frances M. ;

Perez, Edith A. .

ONCOLOGIST, 2010, 15 (10) :1043-1049

[3]

[Anonymous], 2011, AGO LEITL MAMM ADJ C

[4]

[Anonymous], 2011, NCCN GUID VERS 2 201

[5]

Baselga J, 2010, CANC RES S, V70, p82s

[6] Global cancer mortality: The effect of health care system resources on survival from cancer [J].

Batouli, A. ;

Jahanshahi, P. ;

Yu, J. B. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[7]

Bear HD, 2011, J CLIN ONCOL, V29

[8] Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11 th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer) 2009 St. Gallen Conference: Primary Therapy of Early Breast Cancer - Opinion among German Experts (Zurich 2009) [J].

Beckmann, M. W. ;

Blohmer, J-U ;

Costa, S-D ;

Diedrich, K. ;

Diel, I. ;

Eiermann, W. ;

Friese, K. ;

Gerber, B. ;

Harbeck, N. ;

Hilfrich, J. ;

Janni, W. ;

Jaenicke, F. ;

Jonat, W. ;

Kaufmann, M. ;

Kiechle, M. ;

Koehler, U. ;

Kreienberg, R. ;

von Minckwitz, G. ;

Moebus, V. ;

Nitz, U. ;

Schneeweiss, A. ;

Thomssen, C. ;

Wallwiener, D. .

GEBURTSHILFE UND FRAUENHEILKUNDE, 2009, 69 (05) :377-383

[9] Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer:: a randomised trial [J].

Bergh, J ;

Wiklund, T ;

Erikstein, B ;

Lidbrink, E ;

Lindman, H ;

Malmström, P ;

Kellokumpu-Lehtinen, P ;

Bengtsson, NO ;

Söderlund, G ;

Anker, G ;

Wist, E ;

Ottosson, S ;

Salminen, E ;

Ljungman, P ;

Holte, H ;

Nilsson, J ;

Blomqvist, C ;

Wilking, N .

LANCET, 2000, 356 (9239) :1384-1391

[10] Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer [J].

Cameron, DA ;

Massie, C ;

Kerr, G ;

Leonard, RCF .

BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1837-1842

← 1 2 3 4 5 6 7 8 9 10 →